Screening digital rectal examination and prostate cancer mortality: A population-based case-control study

Urology

Volumn 52, Issue 2, 1998, Pages 173-179

  Jacobsen, Steven J ^a   Bergstralh, Erik J ^b   Katusic, Slavica K ^b   Guess, Harry A ^b   Darby, Charles H ^b   Silverstein, Marc D ^b   Oesterling, Joseph E ^b   Lieber, Michael M ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CASE CONTROL STUDY; CONTROLLED STUDY; FINGER; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM; SYMPTOMATOLOGY; UNITED STATES;

AGED; CASE-CONTROL STUDIES; HUMANS; MALE; PALPATION; PROSTATIC NEOPLASMS; RECTUM;

EID: 0032145984     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00171-X     Document Type: Article

References (21)

1. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1998. CA Cancer J Clin. 48:1998;6-29.
2. Denis L.J. To screen or not to screen? Prostate Suppl. 4:1992;63-70.
3. von Eschenbach A., Ho R., Murphy G.P., et al. American Cancer Society guideline for the early detection of prostate cancer update 1997 . CA Cancer J Clin. 47:1997;261-264.
4. Mettlin C.J., Black B., Lee F., et al. Workgroup 2 screening and detection: reference range/clinical issues of PSA . Cancer. 71:1993;2679-2680.
5. Oesterling J.E. Prostate specific antigen a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate . J Urol. 145:1991;907-923.
6. Jacobsen S.J., Katusic S.K., Bergstralh E.J., et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. J Am Med Assoc. 274:1995;1445-1449.
7. Gilliland F.D., Welsh D.J., Hoffman R.M., et al. Rapid rise and subsequent decline in prostate cancer incidence rates for New Mexico, 1989-1993. Cancer Epidemiol Biomark Prev. 4:1995;797-800.
8. Newcomer L.M., Stanford J.L., Blumenstein B.A., et al. Temporal trends in rates of prostate cancer declining incidence of advanced stage disease, 1974 to 1994 . J Urol. 158:1997;1427-1430.
9. Potosky A.L., Miller B.A., Albertsen P.C., et al. The role of increasing detection in the rising incidence of prostate cancer. J Am Med Assoc. 273:1995;548-552.
10. Gohagan J.K., Prorok P.C., Kramer B.S., et al. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial of the National Cancer Institute. Cancer. 75:(7 suppl):1995;1869-1873.
11. Schröder F.H., Bangma C.H. The European Randomized Study of Screening for Prostate Cancer (ERSPC). Br J Urol. 79:(suppl 1):1997;68-71.
12. Weiss N.S. Application of the case-control method in the evaluation of screening. Epidemiol Rev. 16:1994;102-108.
13. Friedman G.D., Hiatt R.A., Quesenberry C.P. Jr, et al. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet. 337:1991;1526-1529.
14. Friedman G.D. Kaiser Permanente Medical Care Program Northern California and Other Regions . Strom B.L. Pharmacoepidemiology. 1994;187-197 John Wiley & Sons, Chichester, England.
15. Melton L.J. III. History of the Rochester Epidemiology Project. Mayo Clin Proc. 71:1996;266-274.
16. Charlson M.E., Pompei P., Ales K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies development and validation . J Chron Dis. 40:1987;373-383.
17. Miettinen O.S. Theoretical Epidemiology Principles of Occurrence Research . 1985;254-256 John Wiley & Sons, New York.
18. Kahn M, O'Fallon WM, Sicks JD: Attributable Risk. Rochester, Mayo Clinic Technical Report Series #54, Section of Biostatistics, 1997.
19. Morrison A.S. Assessing the value of early treatment nonexperimental studies . Morrison A.S. Screening in Chronic Disease. 1992;74-97 Oxford University Press, New York.
20. Xia Z., Jacobsen S.J., Bergstralh E.J., et al. Secular changes in radical prostatectomy utilization rates in Olmsted County, Minnesota, 1980 to 1995. J Urol. 159:1998;904-908.
21. Jacobsen S.J., Bergstralh E.J., Guess H.A., et al. Predictive properties of serum prostate-specific antigen testing in a community-based setting. Arch Intern Med. 156:1996;2462-2468.